X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare PLETHICO PHARMA with Sterling Biotech - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

PLETHICO PHARMA vs STERLING BIOTECH - Comparison Results

STERLING BIOTECH 
   Change

Sterling Biotech primarily produces and distributes pharmaceutical grade gelatine globally. The company currently has a 7.5% share of the global market for pharmaceutical and nutraceutical gelatines. It has more than 70% market share in India. Sterli... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    PLETHICO PHARMA STERLING BIOTECH PLETHICO PHARMA/
STERLING BIOTECH
 
P/E (TTM) x -1.1 -1.7 - View Chart
P/BV x 0.0 0.1 25.2% View Chart
Dividend Yield % 0.0 0.0 -  

Financials

 PLETHICO PHARMA   STERLING BIOTECH
EQUITY SHARE DATA
    PLETHICO PHARMA
Mar-14
STERLING BIOTECH
Dec-13
PLETHICO PHARMA/
STERLING BIOTECH
5-Yr Chart
Click to enlarge
High Rs39511 3,761.0%   
Low Rs313 920.6%   
Sales per share (Unadj.) Rs604.426.8 2,254.7%  
Earnings per share (Unadj.) Rs32.5-15.0 -217.2%  
Cash flow per share (Unadj.) Rs51.3-5.5 -939.6%  
Dividends per share (Unadj.) Rs00-  
Dividend yield (eoy) %00-  
Book value per share (Unadj.) Rs473.654.9 862.9%  
Shares outstanding (eoy) m34.08267.87 12.7%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x0.40.3 136.0%   
Avg P/E ratio x6.6-0.5 -1,412.0%  
P/CF ratio (eoy) x4.2-1.3 -326.3%  
Price / Book Value ratio x0.50.1 355.4%  
Dividend payout %00-   
Avg Mkt Cap Rs m7,2621,862 390.1%   
No. of employees `000NA1.4 0.0%   
Total wages/salary Rs m1,596547 291.9%   
Avg. sales/employee Rs ThNM5,303.3-  
Avg. wages/employee Rs ThNM403.8-  
Avg. net profit/employee Rs ThNM-2,959.0-  
INCOME DATA
Net Sales Rs m20,5987,181 286.9%  
Other income Rs m38643 906.9%   
Total revenues Rs m20,9847,223 290.5%   
Gross profit Rs m2,818947 297.6%  
Depreciation Rs m6422,543 25.3%   
Interest Rs m1,5934,377 36.4%   
Profit before tax Rs m969-5,931 -16.3%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m-138-1,924 7.2%   
Profit after tax Rs m1,107-4,007 -27.6%  
Gross profit margin %13.713.2 103.7%  
Effective tax rate %-14.332.4 -44.0%   
Net profit margin %5.4-55.8 -9.6%  
BALANCE SHEET DATA
Current assets Rs m18,87714,335 131.7%   
Current liabilities Rs m11,89649,809 23.9%   
Net working cap to sales %33.9-494.0 -6.9%  
Current ratio x1.60.3 551.4%  
Inventory Days Days36403 8.9%  
Debtors Days Days198171 115.9%  
Net fixed assets Rs m9,86155,432 17.8%   
Share capital Rs m341268 127.2%   
"Free" reserves Rs m12,33113,935 88.5%   
Net worth Rs m16,13914,701 109.8%   
Long term debt Rs m4,7069,478 49.7%   
Total assets Rs m33,14673,988 44.8%  
Interest coverage x1.6-0.4 -453.0%   
Debt to equity ratio x0.30.6 45.2%  
Sales to assets ratio x0.60.1 640.3%   
Return on assets %8.10.5 1,626.3%  
Return on equity %6.9-27.3 -25.2%  
Return on capital %12.3-6.4 -191.3%  
Exports to sales %21.425.9 82.5%   
Imports to sales %15.20.2 8,961.0%   
Exports (fob) Rs m4,4021,860 236.7%   
Imports (cif) Rs m3,13612 25,704.9%   
Fx inflow Rs m4,4021,860 236.7%   
Fx outflow Rs m3,18425 12,791.9%   
Net fx Rs m1,2191,835 66.4%   
CASH FLOW
From Operations Rs m2,4371,719 141.8%  
From Investments Rs m-6,265-3,148 199.0%  
From Financial Activity Rs m2,4901,426 174.6%  
Net Cashflow Rs m-1,337-3 39,328.2%  

Share Holding

Indian Promoters % 82.7 33.9 244.0%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 4.3 0.0 -  
FIIs % 5.5 9.9 55.6%  
ADR/GDR % 0.0 16.9 -  
Free float % 7.5 39.3 19.1%  
Shareholders   10,665 21,482 49.6%  
Pledged promoter(s) holding % 85.7 55.9 153.3%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare PLETHICO PHARMA With:   NATCO PHARMA  PANACEA BIOTECH  WOCKHARDT LTD.  ABBOTT INDIA  FRESENIUS KABI ONCO.  

Compare PLETHICO PHARMA With:   MYLAN (US)  ADCOCK INGRAM (S. Africa)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Finishes Marginally Lower; Capital Goods & Realty Stocks Fall(Closing)

Indian share markets witnessed selling pressure in the final hour of trade to finish just below the dotted line. At the closing bell, the BSE Sensex closed lower by 71 points.

Related Views on News

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

Biocon: US Pricing Pressure Takes Toll (Quarterly Results Update - Detailed)

Feb 2, 2018

Pricing pressure in the US and costs of the Malaysian facility hit Biocon's profits in the third quarter.

Shalby Ltd. (IPO)

Dec 2, 2017

Should you subscribe to the IPO of Shalby Ltd?

More Views on News

Most Popular

Follow India's Super Investors to Make Big Money in the Market Crash(The 5 Minute Wrapup)

Feb 8, 2018

Has the sell-off in the markets left India's super investors unduly worried?

The Era of Easy Money is Coming to an End. What Happens Now?(Vivek Kaul's Diary)

Feb 9, 2018

The easy money policy of the Federal Reserve of the United States, which drove up stock markets all over the world, is ending, with the Federal Reserve looking to shrink its balance sheet.

The Markets Want Your Money. Don't Give It to Them.(Smart Contrarian)

Feb 9, 2018

MFs are having a gala time taking money from over-eager investors and funneling it into equities. Smart investors, though, know better than to do that.

The Big Gamble(The Honest Truth)

Feb 15, 2018

Once you accept the fact that elections are round the corner and that this budget is geared to reach a 40% target, everything makes sense.

Rising Dominance of Mutual Funds(Chart Of The Day)

Feb 8, 2018

Domestic money flow into Indian equities surpassed foreign fund flows in the recent years. But will it continue in volatile market?

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

PLETHICO PHARMA SHARE PRICE


Jun 13, 2016 (Close)

TRACK PLETHICO PHARMA

  • Track your investment in PLETHICO PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON PLETHICO PHARMA

PLETHICO PHARMA 5-YR ANALYSIS

COMPARE PLETHICO PHARMA WITH

MARKET STATS